PURPOSE: To study the effect of radiation dose on local failure (LF) and distant metastasis (DM) in prostate cancer patients treated with external beam radiotherapy. METHODS AND MATERIALS: The study sample consisted of 919 Stage T1-T3N0M0 patients treated with radiotherapy alone. Three separate dose groups were analyzed: <72 Gy (n = 552, median dose, 68.4 Gy), > or =72 but <82 Gy (n = 215, median dose, 78 Gy), and > or =82 Gy (n = 152, median dose, 83 Gy). The median follow-up period for all patients and those receiving <72 Gy, > or =72 but <82 Gy, and > or =82 Gy was 97, 112, 94, and 65 months, respectively. RESULTS: For all patients, the LF rate at 10 and 15 years was 6% and 13%, respectively. The 7-year LF rate stratified by dose group (<72 Gy, > or =72 but <82 Gy, and > or =82 Gy) was 6%, 2%, and 2%, respectively (p = 0.012). For all patients, the DM rate at 10 and 15 years was 10% and 17%, respectively. The 7-year DM rate stratified by dose group (<72 Gy, > or =72 but <82 Gy, and > or =82 Gy) was 9%, 6%, and 1%, respectively (p = 0.008). Multivariate analysis revealed T stage (p < 0.001), pretreatment prostate-specific antigen level (p = 0.001), Gleason score (p < 0.001), and dose (p = 0.018) to be independent predictors of DM. For all 919 patients, multivariate analysis revealed only Gleason score (p = 0.009) and dose (p = 0.004) to be independent predictors of LF. CONCLUSION: Although the effect of increasing radiation doses has been documented mostly for biochemical failure rates, the results of our study have shown a clear association between greater radiation doses and lower LF and DM rates.
PURPOSE: To study the effect of radiation dose on local failure (LF) and distant metastasis (DM) in prostate cancerpatients treated with external beam radiotherapy. METHODS AND MATERIALS: The study sample consisted of 919 Stage T1-T3N0M0 patients treated with radiotherapy alone. Three separate dose groups were analyzed: <72 Gy (n = 552, median dose, 68.4 Gy), > or =72 but <82 Gy (n = 215, median dose, 78 Gy), and > or =82 Gy (n = 152, median dose, 83 Gy). The median follow-up period for all patients and those receiving <72 Gy, > or =72 but <82 Gy, and > or =82 Gy was 97, 112, 94, and 65 months, respectively. RESULTS: For all patients, the LF rate at 10 and 15 years was 6% and 13%, respectively. The 7-year LF rate stratified by dose group (<72 Gy, > or =72 but <82 Gy, and > or =82 Gy) was 6%, 2%, and 2%, respectively (p = 0.012). For all patients, the DM rate at 10 and 15 years was 10% and 17%, respectively. The 7-year DM rate stratified by dose group (<72 Gy, > or =72 but <82 Gy, and > or =82 Gy) was 9%, 6%, and 1%, respectively (p = 0.008). Multivariate analysis revealed T stage (p < 0.001), pretreatment prostate-specific antigen level (p = 0.001), Gleason score (p < 0.001), and dose (p = 0.018) to be independent predictors of DM. For all 919 patients, multivariate analysis revealed only Gleason score (p = 0.009) and dose (p = 0.004) to be independent predictors of LF. CONCLUSION: Although the effect of increasing radiation doses has been documented mostly for biochemical failure rates, the results of our study have shown a clear association between greater radiation doses and lower LF and DM rates.
Authors: Cédric Draulans; Robin De Roover; Uulke A van der Heide; Linda Kerkmeijer; Robert J Smeenk; Floris Pos; Wouter V Vogel; James Nagarajah; Marcel Janssen; Sofie Isebaert; Frederik Maes; Cindy Mai; Raymond Oyen; Steven Joniau; Martina Kunze-Busch; Karolien Goffin; Karin Haustermans Journal: Eur J Nucl Med Mol Imaging Date: 2020-10-06 Impact factor: 9.236
Authors: Michael J Zelefsky; James A Eastham; Angel M Cronin; Zvi Fuks; Zhigang Zhang; Yoshiya Yamada; Andrew Vickers; Peter T Scardino Journal: J Clin Oncol Date: 2010-02-16 Impact factor: 44.544
Authors: S M Schwarzenböck; J Kurth; Ch Gocke; T Kuhnt; G Hildebrandt; B J Krause Journal: Eur J Nucl Med Mol Imaging Date: 2013-04-11 Impact factor: 9.236
Authors: Irene M Lips; Uulke A van der Heide; Karin Haustermans; Emile N J T van Lin; Floris Pos; Stefan P G Franken; Alexis N T J Kotte; Carla H van Gils; Marco van Vulpen Journal: Trials Date: 2011-12-05 Impact factor: 2.279
Authors: Grant K Hunter; Chandana A Reddy; Eric A Klein; Patrick Kupelian; Kenneth Angermeier; James Ulchaker; Nabil Chehade; Andrew Altman; Jay P Ciezki Journal: Prostate Cancer Date: 2012-04-11